This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collen, D. Articles by Verstraete, M. Search for Related Content PubMed PubMed Citation Articles by Collen, D. Articles by Verstraete, M.

Circulation, Vol 73, 511-517, Copyright © 1986 by American Heart Association

ARTICLES

Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction

D Collen, H Bounameaux, F De Cock, HR Lijnen and M Verstraete

Coagulation and fibrinolysis were studied in patients with acute myocardial infarction during intravenous infusion of recombinant human tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 90 min, n = 101), streptokinase (1,500,000 IU over 60 min, n = 61), or placebo (n = 40). In the rt-PA group, the plasma level of rt-PA antigen was 1.2 +/- 0.6 micrograms/ml (mean +/- SD) and the euglobulin fibrinolytic activity (EFA) was 910 +/- 735 IU t-PA/ml. In the streptokinase group, the EFA was equivalent to 430 +/- 435 IU t-PA/ml. At the end of the infusion, the plasma fibrinogen level measured with a coagulation rate assay was decreased to 57 +/- 33% of the preinfusion value in the rt-PA group, to 7 +/- 10% in the streptokinase group, and remained unchanged in the placebo group. Fibrinogen-fibrin degradation products increased to 0.75 +/- 0.54 mg/ml in the streptokinase group but to only 0.10 +/- 0.13 mg/ml in the rt-PA group. The plasma levels of alpha 2- antiplasmin, plasminogen, and factor V decreased to between 30% and 45% in the rt-PA group but significantly more in the streptokinase group (to between 15% and 25%). Thus rt-PA induced much less systemic fibrinolytic activation than streptokinase. In the patients who received rt-PA, a weak correlation (r = .21, n = 89, .1 greater than p greater than .05) was found between the extent of fibrinogen breakdown at 90 min and the plasma rt-PA concentration.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				A. Ziakas, S. Gavrilidis, G. Giannoglou, E. Souliou, K. Gemitzis, D. Kalampalika, M. A. Vayona, I. Pidonia, G. Parharidis, and G. Louridas In-Hospital and Long-Term Prognostic Value of Fibrinogen, CRP, and IL-6 Levels in Patients with Acute Myocardial Infarction Treated with Thrombolysis Angiology, May 1, 2006; 57(3): 283 - 293. [Abstract] [PDF]

				P. Trouillas and R. von Kummer Classification and Pathogenesis of Cerebral Hemorrhages After Thrombolysis in Ischemic Stroke Stroke, February 1, 2006; 37(2): 556 - 561. [Abstract] [Full Text] [PDF]

				P. Trouillas, L. Derex, F. Philippeau, N. Nighoghossian, J. Honnorat, M. Hanss, P. Ffrench, P. Adeleine, and M. Dechavanne Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis: A Study of 157 Cases Stroke, June 1, 2004; 35(6): 1323 - 1328. [Abstract] [Full Text] [PDF]

				D. Stewart, M. Kong, V. Novokhatny, G. Jesmok, and V. J. Marder Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage Blood, April 15, 2003; 101(8): 3002 - 3007. [Abstract] [Full Text] [PDF]

				H.R. Lijnen, K. Okada, O. Matsuo, D. Collen, and M. Dewerchin alpha 2-Antiplasmin Gene Deficiency in Mice Is Associated With Enhanced Fibrinolytic Potential Without Overt Bleeding Blood, April 1, 1999; 93(7): 2274 - 2281. [Abstract] [Full Text] [PDF]

				W. P. Fay, J. G. Murphy, and W. G. Owen High Concentrations of Active Plasminogen Activator Inhibitor-1 in Porcine Coronary Artery Thrombi Arterioscler Thromb Vasc Biol, October 1, 1996; 16(10): 1277 - 1284. [Abstract] [Full Text]

				S. Anand and S. L. Diamond Computer Simulation of Systemic Circulation and Clot Lysis Dynamics During Thrombolytic Therapy That Accounts for Inner Clot Transport and Reaction Circulation, August 15, 1996; 94(4): 763 - 774. [Abstract] [Full Text]

				J. Meehan Carr, E. G. Bovill, R. P. Tracy, M. Mankowski, K. G. Mann, and J. McDonagh Changes in Fibrinogen After rt-PA Administration Clinical and Applied Thrombosis/Hemostasis, January 1, 1996; 2(1): 43 - 50. [Abstract] [PDF]

				E. Madison, A Kobe, M. Gething, J. Sambrook, and E. Goldsmith Converting tissue plasminogen activator to a zymogen: a regulatory triad of Asp-His-Ser Science, October 15, 1993; 262(5132): 419 - 421. [Abstract] [PDF]

				E. G. Bovill, M. L. Terrin, D. C. Stump, A. D. Berke, M. Frederick, D. Collen, F. Feit, J. M. Gore, L. D. Hillis, C. T. Lambrew, et al. Hemorrhagic Events during Therapy with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin for Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial Ann Intern Med, August 15, 1991; 115(4): 256 - 265. [Abstract] [PDF]

				D. C. Sane, R. M. Califf, E. J. Topol, D. C. Stump, D. B. Mark, and C. S. Greenberg Bleeding during Thrombolytic Therapy for Acute Myocardial Infarction: Mechanisms and Management Ann Intern Med, December 15, 1989; 111(12): 1010 - 1022. [Abstract] [PDF]